NeuroPace, Inc.
NPCEHealthcareNASDAQMedical Devices · Last scanned Jul 18, 2026
Scan Results
Daily timeframeNeuroPace, Inc. operates as a medical device company in the United States. Valued at $548.2M, NPCE is a small-cap name in its sector. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Market Cap
$548.2M
Beta
1.89
P/E (TTM)
—
P/E (Fwd)
-54.10
EPS (TTM)
$-0.65
EPS (Fwd)
$-0.30
ROE
-111.4%
ROA
-10.0%
Cash
$54.0M
Total Debt
$70.5M
Free CF
-$2.7M
52W Change
77.5%
Annual Financials
Cash vs Debt
The company holds $54.0M in cash, though total debt stands at $70.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$2.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -111.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $45.5M (2022) to $100.0M (2025), reflecting a 120% increase over the period.
NeuroPace, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NeuroPace, Inc.'s trajectory.